Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

CANCER RESEARCH

AMER ASSOC CANCER RESEARCH

1. NRG [U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868]
2. NCI BIQSFP
3. BCRF
4. Genentech
5. AstraZeneca